Cigna, through its Evernorth Behavioral Health division, announced it will eliminate prior authorization requirements for transcranial magnetic stimulation (TMS) among its contracted providers. This move aims to speed up treatment access for over 18 million insured individuals across 12 states. Additionally, Evernorth is strengthening its humanitarian efforts by partnering with Direct Relief to distribute essential medications during disasters, expanding its health expertise beyond traditional care. These initiatives are viewed as positive drivers for Cigna's future positioning and growth.

Cigna Group, through its Evernorth division, has launched a new medication donation program in partnership with the humanitarian organization Direct Relief. This innovative initiative enables the rapid distribution of over 41,000 essential prescriptions to disaster-stricken areas by allowing humanitarian groups to source directly from participating pharmacies. The collaboration highlights Evernorth's capabilities and could enhance Cigna's reputation for social responsibility and innovation in healthcare services, strengthening its market position.

Cigna Group (NYSE: CI) reported Q4 2025 results that surpassed expectations, with sales rising 10.4% to $72.5 billion, driven by higher specialty volumes and its new PBM model. Despite a 2026 outlook slightly below forecasts, the company raised its earnings guidance, supported by strategic investments and major regulatory developments. These factors are expected to strengthen Cigna's position in the health insurance market, although elevated costs and a slight decline in some customer segments warrant monitoring.